The role of anti-LeY antibody in the downregulation of MAPKs/COX-2 pathway in gastric cancer

Current Drug Targets

Volumn 15, Issue 4, 2014, Pages 469-476

  Aziz, Faisal ^a   Qiu, Yan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; FUTs; Gastric cancer; H. pylori; Lewis Y; MAPKs; NSAIDs

Indexed keywords

ANTIGEN; CYCLOOXYGENASE 2; FUCOSYLTRANSFERASE; LEY ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL INVASION; ENZYME ACTIVITY; FUCOSYLATION; GENE EXPRESSION; GLYCOSYLATION; HELICOBACTER PYLORI; HUMAN; METASTASIS; REVIEW; STOMACH CANCER; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; CYCLOOXYGENASE 2; GLYCOSYLATION; HELICOBACTER PYLORI; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MAP KINASE SIGNALING SYSTEM; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896328389     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140217152042     Document Type: Review

References (100)

1. Ye YW, Hu S, Shi YQ, et al. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. Oncol Rep 2013; 30(6): 2777-84.
2. Geng M, Wang L, Li P. Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer. Int J Clin Exp Pathol 2013; 6(11): 2554-9.
3. Zhao Y, Hao Y, Ji H, et al. Combinational effect of salvianolic acid B with low dose celecoxib on inhibition of head squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) 2010; 3(6): 787-96.
4. Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitors and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61(6): 812-8.
5. Yang X, Liu S, Liu Y, Liu J, Liu T, Wang X, Yan Q. Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activation MAPK and P13K/Akt signaling pathways. J Cell Physiol 2010; 225(2): 612-9.
6. Yang X, Zhang Z, Jia S, Liu Y, Wang X, Yan Q. Overexpression of fucosyltransferase IV in A431 cell line increase cell proliferation. Int J Biochem Cell Biol 2007; 39(9): 1722-30.
7. Cebola I, Peinado MA. Epigenetic deregulation of the COX pathway in cancer. Prog Lipid Res 2012; 51(4): 301-13.
8. Yang HB, Cheng HC, Sheu BS, et al. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 25(4): 455-61.
9. Zhang LJ, Wang SY, Huo XH, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous of gastric lesions. World J Gastroenterol 2009; 15(22): 2731-8.
10. Clarke K, Lee FT, Brechbiel MW, et al. In vivo bio distribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000; 60(17): 4804-11.
11. Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabelled anti-Lewis Y humanized monoclonal antibody hu3S193 and Palictaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006; 47(4): 716-25.
12. Aziz F, Yang X, Wang XQ, Yan Q. Helicobacter Pylori Infection Leads to Gastric Cancer with the coexpression of Lewis Y and CA724. Glycoconj J 2013; 30: 411.
13. Kalgutkar AS, Zhao Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti cancer agents. Curr Drug Targets 2001; 2(1): 79-106.
14. Zhu Y, Zhou X, Wu J, Su J, Zhang G. Risk factors and prevalence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in Yangzhong city. Gastroenterol Res Pract 2014; 2014: 481365.
15. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, Inoue M. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011; 17(39): 4421-8.
16. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4-66.
17. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008; 23: 8-22.
18. Aziz F, Sherwani SK, Akhtar SS, Kazmi SU. Development of an in-house enzyme-linked immunosorbent assay based on surface whole cell antigen for diagnosis of Helicobacter pylori infection in patients with gastroduodenal ulcer disease. World J Microbiol Biotechnol 2014; 30(1): 305-15.
19. De la Cruz-Herrara CF, Flores-Luna L, Guterrez-Xicotencatl L, Chihu-Amparan L, et al. IgG2 response and low IgG titre specific to Helicobacter pylori CagA as serological markers for gastric cancer. J Med Microbiol 2013; 62: 591-8.
20. Cheng J, Fan XM. Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol 2013; 19(42): 7361-8.
21. Garcia-Del Portillo F, Pucciarelli MG, Casadesus. DNA adenine methylase mutants of Salmonella typhimurium show defects in protein secretion, cell invasion, and M cell cytotoxicity. J. Proc Natl Acad Sci USA 1999; 96(20): 11578-83.
22. Heithoff DM, Sinsheimer RL, Low DA, Mahan M. An essential role for DNA adenine methylation in bacterial virulence. J. Science 1999; 284: 967-70.
23. Rebecca A Herbertson. Optimising targeted antibodies for the treatment of metastatic solid tumours. PhD thesis, University of Nottingham, 2009.
24. Krishnan K, Campbell S, Abdel-Rahman F, Whaley S, Stone WL. Cancer chemoprevention drug targets. Curr Drug Targets 2003; 4(1): 45-54.
25. Kuo CH, Hu HM, Tsai PY, et al. Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol 2009; 15(39): 4907-14.
26. Wang R, Guo L, Wang P, Yang W, Lu Y, Huang Z, Tang C. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 2013; 19(1): 115-25.
27. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23(15): 3536-44.
28. Patel S, Vetale S, Teli P, Mistry R, Chiplunkar S. IL-10 production in non-small cell lung carcinoma patients in regulated by ERK, P38 and COX-2. J Cell Mol Med 2012; 16(3): 531-44.
29. Kim EJ, Raval AP, Hirsch N, Perez-Pinzon MA. Ischemic preconditioning mediates cyclooxygenase-2 expression via nuclear factorkappa B activation in mixed cortical neuronal cultures. Transl Stroke Res 2010; 1(1): 40-7.
30. Lin C, Crawford DR, Lin S, Hwang J, et al. Inducible COX-2-dependent apoptosis in human ovarian cancer cells. Carcinogenesis 2011; 32(1): 19-26.
31. Wang H, Zhu QW, Ye P, et al. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. Biosci Trends 2012; 6(6): 325-32.
32. Fang JF, Liang Y, Du JY, Fang JQ. Transcutaneous electrical nerve stimulation attenuates CFA-induced hyperalgesia and inhibits spinal ERK1/2-COX-2-pathway activation in rats. BMC Complement Altern Med 2013; 13(1): 134.
33. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005; 175(12): 8242-52.
34. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol 2012; 18(18): 2147-60.
35. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus. Gastric Cancer 2013; [Epub ahead of print].
36. Oldham RK. Monoclonal antibodies in cancer therapy. J Clin Oncol 1983; 1(9): 582-90.
37. Zhu K, Amin MA, Zha Y, Harlow LA, Koch AE. Mechanism by which H-2g, a glucose analog of blood group H antigen, mediates angiogenesis. Blood 2005; 105(6): 2343-9.
38. Kelly MP, Lee FT, Tahtis K, et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm 2008; 23(4): 411-23.
39. Lee FT, Mountain AJ, Kelly MP, Hall C, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A"-DTPA-hu3S193 inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 2005; 11(19 Pt 2): 7080s-6s.
40. Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Radioimmunotherapy with alpha-particle emitting 213Bi-Cfunctionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 2007; 13(18 Pt 2): 5604s-5612s.
41. Reis CA, Osorio H, Silva L, Gomes C, David L. Alteration in glycosylation as biomarkers for cancer detection. J Clin Pathol 2010; 63(4): 322-9.
42. Ma R, Matthew Decker N, Anilus V, et al. Post-translational and transcription regulation of glycolipids glycosyltransferases genes in apoptotic breast carcinoma cells: VII. Studied by DNA-microarray after treatment with L-PPMP. Glycoconj J 2009; 26(6): 647-61.
43. Marcos NT, Magalhães A, Ferreira B, et al. Helicobacter pylori induces beta3GnT5 in human gastric cell lines, modulation expression of the SabA ligand sialyl-LewisX. J Clin Invest 2008; 18(6): 2325-36.
44. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008; 143(6): 725-9.
45. Moriwaki K, Miyoshi E. Fucosylation and gastrointestinal cancer. World J Hepatol 2010; 2(4): 151-61.
46. Kawai S, Kato S, Imai H, Okada Y. Suppression of FUT1 attenuates cell proliferation in the HER2-ovIshioka erexpression cancer cell line NCI-N87C. Oncol Rep 2013; 29(1): 13-20.
47. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse-Olson K. Cancer vaccines and carbohydrates epitopes. Vaccine 2011; 29(48): 8802-26.
48. Liu JJ, Lin B, Hao YY, et al. Lewis(y) antigen stimulates the growth of ovarian cancer cell via regulation of the epidermal growth factor receptor pathway. Oncol Rep 2010; 23(3): 833-41.
49. Hanson S, Best M, Bryan MC, Wong CH. Chemoenzymatic synthesis of oligosaccharides and glycoproteins. Trends Biochem Sci 2004; 29: 656-63.
50. Töpfer-Petersen E, Ekhlasi-Hundrieser M, Tsolova M. Glycobiology of fertilization in the pig. Int J Dev Biol 2008; 52: 717-36.
51. Medvedová L, Farkas R. Hormonal control of protein glycosylation: role of steroids and related lipophilic ligands. Endocr Regul 2004; 38: 65-79.
52. Fukuda M. Carbohydrate-dependent cell adhesion. Bioorg Med Chem 1995; 3: 207-15.
53. Marionneau S, Cailleau-Thomas A, Rocher J, et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 2001; 83(7): 565-73.
54. Martin-Satue M, Marrugat R, Cancelas JA, Blanco. Enhanced expression of alpha(1,3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells. J. Cancer Res 1998; 58: 1544-1550.
55. Tokuda N, Zhang Q, Yoshida S, Kusunoki S, Urano T, Furukawa K, Furukawa K. Genetic mechanisms for the synthesis of fucosyl GM1 in small cell lung cancer cell lines. Glycobiology 2006; 16(10): 916-925.
56. Li H, Tong S, Liu J, Han L, Yang X, Hou H, Yan Q, Wang XQ. Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation. Cell Mol Biol Lett 2012; 17(2): 206-16.
57. Basu, S., Das, K., and Basu, M. In: Oligosaccharides chemistry and biology-A Comprehensive Handbook. "Glycosyltransferases in Glycosphingolipid Biosynthesis". (ed.B. Ernst, P. Sinay, and G. Hart), Wiley-VCH Verlag GmbH Germany 2000; Pages-329 to 347.
58. Wang, X., Gu, J., Ihara, H., Miyoshi, E., Honke, K, Taniguchi, N. Core fucosylation regulates epidermal growth factor receptormediated intracellular signaling. J. Biol. Chem 2006; 281(5): 2572-2577.
59. Javaud C, Dupuy F, Maftah A, Julien R, Petit JM. The fucosyltransferase gene family: an amazing summary of the underlying mechanisms of gene evolution. Genetica 2003; 118(2-3): 157-170.
60. Escrevente C, Machado E, Brito C, Reis CA, Stoeck A, Runz S, Marme A, Altevogt P, Costa J. Different expression levels of alpha3/ 4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. Int. J. Oncol 2006; 29(3): 557-566.
61. Wang H, Ge CH, Kong Y, Xin Y, Zhu ZM. Ovary hormonal control of Le(y) oligosaccharide expression during peri-implantation of mouse endometrium. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2001; 33(5): 542-546.
62. Zhang Z, SunP, Liu J, Fu L, Yan J, Liu Y, Wang x, Yan Q. Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 2008; 1783(2): 287-96.
63. Lunau N, Seelhorst K, Kahl S, Tscherch K, Stacke C, Rohn S, Thiem J, Hahn U, Meier C. Fluorescently labeled substrate for monitoring α1,3-fucosyltransferase IX activitiy. Chemistry 2013; 19(51): 17379-90.
64. Ebel ME, Kansas GS. Defining the functional boundaries of the murine α1,3 fucosyltransferase Fut7 reveals a remarkably compact locus. J Biol Chem 2014. [Epub ahead of print]
65. Higai K, Miyazaki N, Azuma Y, Matsumoto K. Interleukin-1beta induces sialyl Lewis X on Hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3GalIV and FUT VI gene. FEBS Lett 2006; 580(26): 6069-75.
66. Münster J, Ziegelmüller P, Spillner E, Bredehorst R. High level expression of monomeric and dimeric human alpha1,3-fucosyltransferase V. J Biotechnol. 2006; 121(4): 448-57.
67. Togayachi A, Kudo T, Ikehara Y, Iwasaki H, Nishihara S, Andoh T, Higashiyama M, Kodama K, Nakamori S, Narimatsu H. Upregulation of Lewis enzyme (Fuc-T111) and plasma-type alpha 1,3 fucosyltransferase (Fuc-TVI) expression determines the augmented expression of sialyl Lewis x antigen in non-small cell lung cancer. Int J Cancer 1999; 83(1): 70-9.
68. N. Taniguchi, K. Honke, M. Fukuda, et al: In: Handbook of glycosyltransferases and related genes, R. Oriol, R. Mollicone, H. Narimatsu (Eds.), Fucosyltransferases, Springer-Verlag, Tokyo 2002; Pages-205 to 231.
69. Basu M, Hawes JW, Li Z, et al. Biosynthesis in vitro of SA-Lex and SA-diLex by aaa1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissue. Glycobiology 1991; 1: 527-35.
70. Avery OT, Geobel WF. Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533-50.
71. Kayhtyand H, Eskola. New vaccines for the prevention of pneumococcal infections. J. Emerg Infect Dis 1996; 2: 289-98.
72. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171: 885-9.
73. Gilewski T, Ragupathi G, Bhuta S, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci 2001; 98(6): 3270-5.
74. Miles D, Papazisis K. Clin. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Breast Cancer 2003; 3(4): S134-8.
75. Moase EH, Qi W, Ishida T, Gabos Z, et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and theratope: STn-KLH cancer vaccine. Bone Marrow Transpl 2000; 25(12); 1233-41.
76. Cipolla L, Rescigno M, Leone A, Peri F, La Ferla B, Nicotra F. Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines. Bioorg Med Chem 2002; 5: 1639-46.
77. Buskas T, Ingale S, Boons GJ. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lapidated glycopeptide containing the tumorassociated tn antigen. Angew Chem Int Ed Engl 2005; 37: 5985-8.
78. Nishihara S, Iwasaki H, Kaneko M, Tawada A, Ito M, Narimatsu H. HH1,3-Fucosyltrasferase 9 (FUT9; Fuc-TIX) preferentially fucosylates the distal GlcNAc residue of polylactosamine chain while the other four tt1,3FUT members preferentially fucosylate the inner GlcNAc residue. FEBS Lett 1999; 462: 289-94.
79. Azuma Y, Kurusu Y, Sato H, Higai K, Matsumoto K. Increased expression of Lewis x and y antigens on the cell surface and FUT4 mRNA during granzyme B-induced Jurkat cell apoptosis. Biol Pharm Bull 2007; 30: 655-60.
80. Handa K, Hakomori SI. Carbohydrate to carbohydrate interaction in developmental process and tumor progression. Glycoconj J 2012; 29(8-9): 627-37.
81. B.S. Sheu, S.M. Sheu, H.B. Yang, A.H. Huang, J.J.W. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. Gut 2003; 52(7): 927-32.
82. Wang XQ, Zhu ZM, Fenderson BA, Zeng GQ, Cao YJ, Jiang GT. Effects of monoclonal antibody directed to LeY on implantation in the mouse. Mol Hum Reprod 1998; 4(3): 295-300.
83. Dettke M, Pálfi G, Pursch E, Fischer MB, Loibner H. Increased expression of the blood group-related Lewis Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases. Rheumatology (Oxford) 2001; 40(9): 1033-7.
84. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 2005; 7(5): 780-7.
85. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997; 73: 50-6.
86. Petretti T, Schulze B, Schlag PM, Kemmner W. Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta 1999; 1428: 209-18.
87. Ito H, Hiraiwa N, Sawada-Kasugai M, et al. Altered mRNA expression of specific molecular species of fucosyl-and sialyltransferases in human colorectal cancer tissues. Int J Cancer 1997; 71: 556-64.
88. Kudo T, Ikehara Y, Togayachi A, et al. Up-regulation of a set of glycosyltransferases genes in human colorectal cancer. Lab Invest 1998; 78: 797-811.
89. Liu J, Lin B, Hao Y, et al. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the P13K/Akt signaling pathway. J Exp Clin Cancer Res 2009; 28: 154.
90. Liu D, Liu J, Lin B, et al. Lewis y regulate cell cycle related factor in ovarian carcinoma cell RMG-1 in vitro via ERK and Akt signaling pathway. Int J Mol Sci 2012; 13(1): 828-39.
91. Chrysogelos SA, Dickson RB. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 1994; 29: 29-40.
92. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003; 22: 5866-5875.
93. Goel S, Hidalgo M, Perez-Soler R. EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 2007; 6: 305-320.
94. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18(11): 2282-92.
95. Daniel Oruzio, Günter Waxenecker, Christoph Aulmann, et al. Phase I dose escalation study with the lewis Y carbohydrate specific humanized antibody IGN311. JCT 2011; 2(5): 760-71.
96. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 2000; 6(9): 3621-8.
97. Lee FT, Mountain AJ, Kelly MP, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A "-DTPA-huS193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR kinase inhibitor. Clin Cancer Res 2005; 11(19): 7080s-6s.
98. Szolar OH, Stranner S, Zinoecker I, et al. Qualification and application a surface Plasmon resonance-based assay for monitoring potential responses induced after passive administration of a humanized anti-lewis-Y antibody. J Pharm Biomed Anal 2006; 41(4): 1347-53.
99. Lövqvist A, Humm JL, Sheikh A, et al. PET imaging of (86)Ylabeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86) Y and (111) in radiolabels. J Nucl Med 2001; 42(8): 1281-7.
100. Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53(2): 195-200.